Unleashing ferroptosis for cancer therapy with warfarin

Xiaoguang Liu; Li Zhuang; Boyi Gan

doi:10.1016/j.tem.2023.08.008

Unleashing ferroptosis for cancer therapy with warfarin

Xiaoguang Liu, Li Zhuang, Boyi Gan

Experimental Radiation Oncology

Research output: Contribution to journal › Short survey › peer-review

Abstract

Ferroptosis holds promise for cancer therapy. A recent study by Yang et al. in Cell Metabolism reveals that VKORC1L1-mediated reduction of vitamin K inhibits ferroptosis and establishes a direct p53-VKORC1L1 link in its regulation. As warfarin can inhibit VKORC1L1, the study further underscores this drug's potential as a cancer therapy.

Original language	English (US)
Pages (from-to)	683-684
Number of pages	2
Journal	Trends in Endocrinology and Metabolism
Volume	34
Issue number	11
DOIs	https://doi.org/10.1016/j.tem.2023.08.008
State	Published - Nov 2023

Keywords

ferroptosis
p53
vitamin K
VKORC1L1
warfarin

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.tem.2023.08.008

Cite this

@article{1a5a6a14a6a4459690da14423490a38f,

title = "Unleashing ferroptosis for cancer therapy with warfarin",

abstract = "Ferroptosis holds promise for cancer therapy. A recent study by Yang et al. in Cell Metabolism reveals that VKORC1L1-mediated reduction of vitamin K inhibits ferroptosis and establishes a direct p53-VKORC1L1 link in its regulation. As warfarin can inhibit VKORC1L1, the study further underscores this drug's potential as a cancer therapy.",

keywords = "ferroptosis, p53, vitamin K, VKORC1L1, warfarin",

author = "Xiaoguang Liu and Li Zhuang and Boyi Gan",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = nov,

doi = "10.1016/j.tem.2023.08.008",

language = "English (US)",

volume = "34",

pages = "683--684",

journal = "Trends in Endocrinology and Metabolism",

issn = "1043-2760",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Unleashing ferroptosis for cancer therapy with warfarin

AU - Liu, Xiaoguang

AU - Zhuang, Li

AU - Gan, Boyi

PY - 2023/11

Y1 - 2023/11

N2 - Ferroptosis holds promise for cancer therapy. A recent study by Yang et al. in Cell Metabolism reveals that VKORC1L1-mediated reduction of vitamin K inhibits ferroptosis and establishes a direct p53-VKORC1L1 link in its regulation. As warfarin can inhibit VKORC1L1, the study further underscores this drug's potential as a cancer therapy.

AB - Ferroptosis holds promise for cancer therapy. A recent study by Yang et al. in Cell Metabolism reveals that VKORC1L1-mediated reduction of vitamin K inhibits ferroptosis and establishes a direct p53-VKORC1L1 link in its regulation. As warfarin can inhibit VKORC1L1, the study further underscores this drug's potential as a cancer therapy.

KW - ferroptosis

KW - p53

KW - vitamin K

KW - VKORC1L1

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85169507448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169507448&partnerID=8YFLogxK

U2 - 10.1016/j.tem.2023.08.008

DO - 10.1016/j.tem.2023.08.008

M3 - Short survey

C2 - 37648560

AN - SCOPUS:85169507448

SN - 1043-2760

VL - 34

SP - 683

EP - 684

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

IS - 11

ER -

Unleashing ferroptosis for cancer therapy with warfarin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this